Aldo-ketoreductase 1c19 ablation does not affect insulin secretion in murine islets

Area of Science:

• Endocrinology
• Molecular Biology
• Genetics

Background:

• Beta cell failure is central to diabetes, involving insulin production, secretion, and cell number defects.
• Loss of Foxo1 function, potentially due to hyperacetylation and degradation, is mechanistically linked to beta cell failure.
• Genome-wide analyses identified Foxo1 target genes, including aldo-ketoreductases, as potential mediators of cellular dysfunction.

Purpose of the Study:

• To investigate the role of Akr1c19 in beta cell function and its regulation by Foxo1.
• To determine if Akr1c19 is involved in the beta cell failure observed in diabetes.

Main Methods:

• Genome-wide analyses to identify Foxo1 target genes.
• Chromatin immunoprecipitation to assess Foxo1 binding to aldo-ketoreductase promoters.
• Gain- and loss-of-function experiments in cultured beta cells.
• Generation and analysis of Akr1c19 knockout mice.

Main Results:

• Foxo1 binds to the promoters of Akr1c12, Akr1c13, and Akr1c19.
• Akr1c19 expression is decreased in db/db islets.
• Foxo1 and HNF1a cooperatively regulate Akr1c19 expression.
• Akr1c19 knockout mice and islets showed no abnormalities in glucose homeostasis.

Conclusions:

• Reduced Akr1c19 expression alone is insufficient to cause islet dysfunction or affect glucose homeostasis.
• The precise mechanisms linking Foxo1 dysfunction to beta cell failure require further investigation beyond Akr1c19.